Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Dec;41(12):4199-4208.
doi: 10.1002/hed.25945. Epub 2019 Oct 8.

Reproductive factors and thyroid cancer risk: Meta-analysis

Arathy S Mannathazhathu  1 , Preethi S George  1 , Sreekala Sudhakaran  1 , Durga Vasudevan  1 , Jagathnath Krishna Km  1 , Christopher Booth  2 , Aleyamma Mathew  1
Affiliations
Meta-Analysis

Reproductive factors and thyroid cancer risk: Meta-analysis

Arathy S Mannathazhathu et al. Head Neck. 2019 Dec.

Abstract

Background: Assessed pooled risk on reproductive factors and oral contraceptives (OC) on thyroid cancer (TC) using published studies (1996-2017).

Methods: Summary odds ratio (OR) for case-control studies (n = 10) and risk ratio (RR) for cohort studies (n = 9) was done.

Results: OR was 1.43 (95% CI: 1.16-1.77) for age at menarche >14 years, 1.49 (95% CI: 1.19-1.86) for parity >2, 1.38 (95% CI: 1.18-1.61) for miscarriage/abortion, and 2.05 (95% CI: 1.39-3.01) for artificial menopause. A protective effect (ORs: 0.85; 95% CI: 0.72-0.99) on TC was observed for prolonged use of OCs. RR was 1.17 (95% CI: 0.90-1.57) for age at menarche >14 years, 1.10 (95% CI: 0.94-1.27) for parity >2, 1.20 (95% CI: 1.03-1.40) for miscarriage/abortion, and 2.16 (95% CI: 1.41-3.31) for artificial menopause and protective effect (RR: 0.78; 95% CI: 0.65-0.92) for prolonged use of OCs.

Conclusions: This meta-analysis supports an association due to changes in female hormones during menstrual cycle and pregnancy with the risk of TC and explains female preponderance.

Keywords: meta-analysis; oral contraceptive use; reproductive factors; thyroid cancer.

PubMed Disclaimer

References

REFERENCES

    1. Bray F, Colombet M, Mery L, et al. Cancer Incidence in Five Continents. Vol. XI (electronic version). Lyon, France: International Agency for Research on Cancer; 2017. http://ci5.iarc.fr. Accessed January 2019.
    1. Ortega J, Sala C, Flor B, Lledo S. Efficacy and cost-effectiveness of the UltraCision® harmonic scalpel in thyroid surgery: an analysis of 200 cases in a randomized trial. J Laparoendosc Adv Surg Tech A. 2009;14(1):9-12.
    1. Chen GG, Vlantis AC, Zeng Q, van Hasselt CA. Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer. Curr Cancer Drug Targets. 2008;8(5):367-377.
    1. Kilfoy BA, Devesa SS, Ward MH, et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol Biomarkers Prev. 2009;18(4):1092-1100.
    1. Negri E, Dal Maso L, Ron E, et al. A pooled analysis of case-control studies of thyroid cancer II. Menstrual and reproductive factors. Cancer Causes Control. 1999;10(2):143-155.

MeSH terms

Substances

LinkOut - more resources